Gut microbiome differences between metformin- and liraglutide-treated T2DM subjects

Endocrinology, Diabetes & Metabolism
Zhang WangJames R Brown

Abstract

Metformin and glucagon-like peptide-1 (GLP-1) agonists are widely used for treating type two diabetes mellitus (T2DM). While recent studies suggest these drugs might modify the gastrointestinal tract (GIT) microbiome, further confirmation is required from human clinical trials. Here, we compare, in patients with T2DM, the effects of metformin (n = 18 subjects) and liraglutide (n = 19), a GLP-1 agonist, on their GIT microbiomes over a 42 day period (n = 74 samples) using 16S ribosomal RNA (rRNA) sequencing. We found that these drugs had markedly different effects on the microbiome composition. At both baseline and Day 42, subjects taking metformin had a significant increase (Baseline adj. P = .038, Day 42 adj. P = .041) in the relative abundance of the bacterial genus Sutterella, whereas liraglutide dosing is associated with a significant increase (Baseline adj. P = .048, Day 42 adj. P = .003) in the genus Akkermansia, a GIT bacteria positively associated with gut barrier homoeostasis. Bacteroides and Akkermansia relative abundances were also significantly associated with duration of subject diabetes (adj P < .05). Specifically, there was a significantly higher abundance of Akkermansia in subjects with short and medium durations...Continue Reading

References

Apr 13, 2010·Nature Methods·J Gregory CaporasoRob Knight
Aug 17, 2010·Bioinformatics·Robert C Edgar
May 15, 2013·Proceedings of the National Academy of Sciences of the United States of America·Amandine EverardPatrice D Cani
Jul 10, 2013·Diabetologia·Graham RenaKei Sakamoto
Jul 6, 2014·PloS One·Antonella NapolitanoDerek J Nunez
May 7, 2016·World Journal of Gastrointestinal Surgery·Ming YanWen-Mao Yan
Aug 20, 2016·Inflammatory Bowel Diseases·Claus H Bang-BerthelsenKlaus S Frederiksen

❮ Previous
Next ❯

Citations

Apr 3, 2020·The International Journal of Neuropsychopharmacology·Karolina Skonieczna-ŻydeckaChristoph U Correll
Mar 21, 2019·World Journal of Diabetes·Yevheniia KyriachenkoNazarii Kobyliak
Aug 7, 2019·Annual Review of Pharmacology and Toxicology·Rosina PryorFilipe Cabreiro
Aug 29, 2020·Nature Reviews. Gastroenterology & Hepatology·Arpana GuptaEmeran A Mayer
Jan 29, 2019·Frontiers in Microbiology·Jessica D ForbesNatalie C Knox
Apr 25, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Jing KeDong Zhao
Oct 8, 2020·Nutrients·Juan SalazarValmore Bermudez
Dec 18, 2020·Current Opinion in Lipidology·Manon BalversMax Nieuwdorp
Nov 17, 2020·Frontiers in Cellular and Infection Microbiology·Qi-You DingXiao-Lin Tong
Apr 4, 2021·International Journal of Molecular Sciences·Jinsha LiuSepideh Afshar
May 19, 2021·Pharmacological Reports : PR·Jan Detka, Katarzyna Głombik
Aug 8, 2021·Gut Pathogens·A L CunninghamD A Harris
Dec 6, 2019·Chemical Research in Toxicology·Andrea Nuzzo, James R Brown

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01725126

Software Mentioned

QIIME
UCLUST
R bioconductor
edgeR

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.